Tong Tongyu, Guan Yupeng, Xiong Haiyun, Wang Liling, Pang Jun
Department of Urology, Nephrology and Urology Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Maternal and Child Health Research Institute, Baoan Maternity & Child Healthcare Hospital, Shenzhen, China.
Front Oncol. 2020 Sep 17;10:1541. doi: 10.3389/fonc.2020.01541. eCollection 2020.
Accumulative studies suggest the Glasgow prognostic score (GPS) and modified Glasgow prognostic score (mGPS) to be potential biomarkers; however, their prognostic value remains debatable. Our meta-analysis focused on assessing the accurate prognostic value of GPS and mGPS in patients with renal cell carcinoma (RCC) in addition to their effectiveness. To investigate the relationship between mGPS/GPS and prognostic value in patients with RCC, we performed a comprehensive retrieval of relevant articles from databases such as PubMed, Embase, Web of Science, and Medline up to February 1, 2020. STATA 15.0 software was used to obtain pooled hazard ratios (HRs) and their 95% confidence intervals for survival outcome, including overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS). A formal meta-analysis of these outcomes was performed. In total, 2,691 patients with RCC were enrolled from 15 cohort studies. Higher GPS/mGPS (GPS/mGPS of 2) indicated poorer OS, CSS, PFS, and RFS in patients with RCC. Similarly, medium GPS/mGPS (GPS/mGPS of 1) also had a significant association with poorer OS, CSS, PFS, and RFS but superior than higher GPS/mGPS in these patients. GPS and mGPS are effective biomarkers for predicting prognosis in patients with RCC, and higher GPS and mGPS are closely related to inferior survival outcomes. More randomized controlled trials are needed to investigate the promising value of GPS/mGPS in the future.
累积研究表明，格拉斯哥预后评分（GPS）和改良格拉斯哥预后评分（mGPS）可能是潜在的生物标志物；然而，它们的预后价值仍存在争议。我们的荟萃分析除了评估GPS和mGPS的有效性外，还着重评估其在肾细胞癌（RCC）患者中的准确预后价值。为了研究mGPS/GPS与RCC患者预后价值之间的关系，我们对截至2020年2月1日的PubMed、Embase、Web of Science和Medline等数据库中的相关文章进行了全面检索。使用STATA 15.0软件获得生存结局的合并风险比（HR）及其95%置信区间，包括总生存期（OS）、无复发生存期（RFS）、无进展生存期（PFS）和癌症特异性生存期（CSS）。对这些结局进行了正式的荟萃分析。总共从15项队列研究中纳入了2691例RCC患者。较高的GPS/mGPS（GPS/mGPS为2）表明RCC患者的OS、CSS、PFS和RFS较差。同样，中等GPS/mGPS（GPS/mGPS为1）也与较差的OS、CSS、PFS和RFS显著相关，但在这些患者中优于较高的GPS/mGPS。GPS和mGPS是预测RCC患者预后的有效生物标志物，较高的GPS和mGPS与较差的生存结局密切相关。未来需要更多的随机对照试验来研究GPS/mGPS的潜在价值。
